Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nucleartranslocation via regulating PI3K/Akt pathway
50 mg/kg) for 28 consecutive days to establish chronic epilepsy models
once a day for 3 days) blocks carrageenan-induced increase in leukocyte number and protein levels in air pouch exudates in mice
3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]propanamido]-3-(1H-indol-3-yl)propanamido]-4-methylpentanamido]-3-methylbutanamido]-N-({[(1S)-1-carbamoyl-4-[(diaminomethylidene)amino]butyl]carbamoyl}methyl)hexanamide
5 min) binds to IRES-A (WT) and IRES-A mutant RNA oligomer (IRES-MU1) with Kds of 1
RBN-2397 Catalog No.:M26339-C Glaucocalyxin A exerts anticancer effectRBN 2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN 2397 selectively binds to PARP7 (Kd=0. 001 M) and restores IFN signaling. RBN 2397 has the potential for the study of advanced or metastatic solid tumors. Product information CAS Number: 2381037 82 5 Molecular Weight: 523. 43 Formula: C20H23F6N7O3 Chemical Name: 5 {[(2S) 1 (3 oxo 3 {4 [5 (trifluoromethyl)pyrimidin 2 yl]piperazin 1
US$ 1170.00
US$ 1170.00
US$ 9537.00
US$ 691.00
US$ 594.00
US$ 691.00
US$ 533.50
US$ 1170.00
US$ 691.00
US$ 691.00
US$ 821.50
US$ 533.50
US$ 658.50
US$ 691.00
US$ 484.00
US$ 712.50
US$ 2651.00